FIELD: biotechnology.
SUBSTANCE: invention relates to a cell containing an exogenous nucleic acid, which provides expression or overexpression of a clostridial neurotoxin receptor or a variant thereof, or a fragment thereof, which has the ability to bind clostridial neurotoxin, an exogenous nucleic acid which provides expression or overexpression of a ganglioside having a clostridial neurotoxin binding affinity, and an exogenous nucleic acid which provides expression or overexpression of an indicator protein cleaved by a clostridial neurotoxin, as well as a method for production thereof.
EFFECT: invention is effective for identifying the composition of Clostridial neurotoxin for therapeutic and cosmetic use, for characterizing the activity of the composition of Clostridial neurotoxin, as well as for analysis for determining activity of modified or recombinant neurotoxin.
42 cl, 13 dwg, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC AND COSMETIC USE OF SEROTYPE E NEUROTOXIN BOTULINUM | 2019 |
|
RU2800604C2 |
| HYBRID NEUROTOXINS | 2017 |
|
RU2782382C2 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2018 |
|
RU2719164C1 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2019 |
|
RU2727402C1 |
| ENGINEERED BOTULINUM NEUROTOXIN | 2016 |
|
RU2746736C2 |
| CONSTRUCTED BOTULINUM NEUROTOXIN | 2017 |
|
RU2789302C2 |
| BOTULINUM NEUROTOXIN BIOHYBRID | 2019 |
|
RU2816855C2 |
| SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS SPECIFICALLY BINDING TO BOTULINUM NEUROTOXIN TYPE A, AND METHOD OF USING THEM FOR THERAPY OR EMERGENCY PREVENTION OF INTOXICATION CAUSED BY BOTULINUM NEUROTOXIN TYPE A | 2021 |
|
RU2766348C1 |
| COMBINED COMPOSITION CONTAINING FGF-18 COMPOUND | 2016 |
|
RU2745453C2 |
| COMPLEX, AGENT AND APPLICATION OF TYPE A BOTULINUM TOXIN CLOSTRIDIUM BOTULINUM | 2020 |
|
RU2783511C1 |
